Washington, D.C. 20549






Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of December, 2023

Commission File Number 001-39670




(Translation of registrant’s name into English)



6 Tide Street, Suite 400

Boston, Massachusetts 02210

(Address of principal executive office)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒                Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐





On May 9, 2022, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”) announced the commencement of a $50 million share repurchase program (the “Program”) of its ordinary shares of one pence each (“Ordinary Shares”). The Company plans to execute the Program in two equal tranches, the first of which was completed on October 26, 2022. In respect of each of the two tranches, PureTech entered into an irrevocable non-discretionary instruction with Jefferies International Limited (“Jefferies”) in relation to the purchase by Jefferies of Ordinary Shares for an aggregate consideration (excluding expenses) of no greater than $25 million and the simultaneous on-sale of such Ordinary Shares by Jefferies to PureTech. Jefferies makes its trading decisions in relation to the Ordinary Shares independently of, and uninfluenced by, the Company. Purchases may continue during any close period to which the Company is subject. Any purchase of Ordinary Shares under the second tranche of the Program are carried out on the London Stock Exchange and any other UK recognized investment exchange which may be agreed, in accordance with pre-set parameters and in accordance with, and subject to limits, including those limits related to daily volume and price, prescribed by the Company’s general authority to repurchase Ordinary Shares granted by its shareholders at its most recent annual general meeting on June 13, 2023, Chapter 12 of the Financial Conduct Authority’s UK Listing Rules, Article 5(1) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) and Commission Delegated Regulation (EU) 2016/1052 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018). All Ordinary Shares repurchased under the Program will be held in treasury.

During the month ended December 31, 2023, the Company had the following daily purchases of its own Ordinary Shares under the Program through Jefferies:




Ordinary Shares


Volume Weighted

Average Price Paid

per Ordinary Share


Highest Price Paid


Lowest Price Paid

December 1, 2023    37,605    150.74p    154.00p    148.20p
December 4, 2023    45,974    152.84p    156.00p    150.00p
December 5, 2023    49,702    148.21p    150.40p    146.20p
December 6, 2023    50,961    150.82p    153.60p    145.00p
December 7, 2023    69,961    144.50p    150.00p    142.40p
December 8, 2023    57,808    141.79p    143.00p    140.40p
December 12, 2023    55,314    143.35p    144.00p    142.20p
December 13, 2023    57,399    143.22p    144.00p    142.40p
December 14, 2023    74,441    145.52p    148.80p    141.80p
December 15, 2023    92,241    147.66p    149.20p    146.00p
December 18, 2023    51,345    150.04p    150.80p    148.00p
December 19, 2023    91,318    152.06p    152.60p    150.00p
December 20, 2023    31,948    154.25p    154.80p    152.00p
December 21, 2023    61,072    150.69p    154.20p    147.00p
December 22, 2023    35,715    152.90p    158.60p    150.80p

During the month ended December 31, 2023, the Company repurchased an aggregate of 862,804 Ordinary Shares. As of December 31, 2023, the Company’s issued share capital was 289,468,159 shares, 17,614,428 of which were held in treasury, resulting in total voting rights in the Company of 271,853,731 shares. To view the details of the individual transactions, please paste the following URL(s) into the address bar of your browser with respect to each individual date of repurchase under the Program:

December 1, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4990121.html

December 4, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4991557.html

December 5, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4993234.html

December 6, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4994843.html

December 7, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4996344.html

December 8, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/4997816.html

December 12, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/5001016.html

December 13, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/5002449.html

December 14, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/5004496.html

December 15, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/5006111.html

December 18, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/5007908.html

December 19, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/5009538.html

December 20, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/5011144.html

December 21, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/5012796.html

December 22, 2023: https://data.fca.org.uk/artefacts/NSM/RNS/5014323.html


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


Date: January 4, 2024   By:   /s/ Daphne Zohar
    Name:   Daphne Zohar
    Title:   Chief Executive Officer